Incyte Corp (INCY)
$86.79 3.63 (4.01%)
19:59 EDT INCY Stock Quote Delayed 30 Minutes
Previous Close $86.79
Market Cap 18.40B
PE Ratio -114.20
Volume (Avg. Vol.) 3.30M
Day's Range 85.65 - 91.00
52-Week Range 62.48 - 110.36
Dividend & Yield N/A (N/A)
INCY Stock Predictions, Articles, and Incyte Corp News
- From InvestorPlace
- From the Web
Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.
Stocks were hit for what feels like the first time in a long time. Here's what happened in the stock market today.
Incyte (INCY) news for Friday about a recent clinical trial failing to meet its endpoints has INCY stock taking a beating.
Activision Blizzard, Incyte and Darden are just some of the stocks to buy for investors looking for gains in September.
With August now upon us, not only is the overbought market vulnerable to profit-taking, the calendar is working against stocks as well. One average, the market loses ground rather than gains ground in the month of August, as well as for September.
Biotech stocks have been looking rough lately, and these four names have been helping to lead the charge lower.
Trump says that Facebook and Alphabet should be sued, while Micron surged on earnings. Semiconductors got a big boost in the Nasdaq today as well.
PayPal, Slack, and chip stocks like AMD and Nvidia, Micron and Nio were all big movers in the Nasdaq today. Get the scoop, now.
Despite the trade dispute with China, these biotech stocks each earn top marks in Portfolio Grader for fundamentals, earnings and momentum.
The stock charts of INCY, LYB and FMC are going to start this week's hump-day at a precipice. Here are the numbers to know.
The stock charts of COG, INCY and SRE are worth a closer technical look at the midpoint of the trading week.
The stock charts of PFE, INCY and MGM are finally making good on previously-suggested promise.
The stock charts of INCY, ABT and SLB are set to end the week on a more definitive, trade-worthy footing than most other names.
The stock charts of SLG, INCY and ETR are shaping up as the best trading bets as the new week kicks off.
Incyte (INCY) was falling hard on Friday following news of a failed Phase 3 drug trial for its melanoma drug epacadostat.
If you’re itching to buy, avoid these stocks at all costs. Here's what makes them stocks to sell for all wise investors.
Navellier RatingsPowered by Portfolio Grader